论文部分内容阅读
目的探讨血清ＣｙＦＲＡ２１１和癌胚抗原（ＣＥＡ）对非小细胞肺癌（ＮＳＣＬＣ）的临床价值。方法采用免疫放射分析方法对３０例经临床和病理证实的ＮＳＣＬＣ患者和２０例正常人进行血清ＣｙＦＲＡ２１１和ＣＥＡ联合测定。结果血清ＣｙＦＲＡ２１１值在ＮＳＣＬＣ组的阳性率为４８％，鳞癌组阳性率为６２５％，分别明显高于正常组和腺癌组（Ｐ＜００１）；且与分期有关，Ⅱ期阳性率为３３３％，Ⅲ期为６６７％，Ⅳ期为７２％。血清ＣＥＡ值在ＮＳＣＬＣ组阳性率为４０％，腺癌中阳性率为５０％，分别明显高于正常组和其他类型（Ｐ＜００１）。联合检测ＣｙＦＲＡ２１１和ＣＥＡ可将整个ＮＳＣＬＣ组阳性率提高到６３２％。结论两者联合检测对ＮＳＣＬＣ的诊断、分型、分期和预后判断有一定的临床意义。
Objective To investigate the clinical value of serum CyFRA211 and carcinoembryonic antigen (CEA) in nonsmall cell lung cancer (NSCLC). Methods Immunoradiometric assay was used to detect serum CyFRA211 and CEA in 30 cases of clinically and pathologically confirmed NSCLC patients and 20 normal controls. Results The positive rate of CyFRA211 in the NSCLC group was 48%, and the positive rate in the squamous cell carcinoma group was 62.5%, which was significantly higher than that in the normal and adenocarcinoma groups, respectively (P<001). It was also related to the staging. The positive rate in phase II was 33. 3%, 66.7% in phase III, and 72% in phase IV. The positive rate of serum CEA in NSCLC group was 40%, and the positive rate in adenocarcinoma was 50%, which was significantly higher than that of normal group and other types, respectively (P<001). Combined detection of CyFRA21 1 and CEA increased the positive rate of the entire NSCLC group to 63. 2%. Conclusion The combined detection of both has clinical significance for the diagnosis, classification, staging and prognosis of NSCLC.